Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2000 • 2,981 citations

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 • 2,187 citations

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

2007 • 1,953 citations

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

2004 • 1,810 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

2007 • 1,562 citations

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 • 1,432 citations

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

2005 • 1,418 citations

BRAF mutation predicts sensitivity to MEK inhibition

2005 • 1,312 citations

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

2007 • 1,111 citations

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

2005 • 948 citations

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

2004 • 889 citations

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 • 827 citations

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

2007 • 817 citations

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

2007 • 737 citations

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

2008 • 735 citations

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

2007 • 533 citations

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

2006 • 516 citations

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

2008 • 461 citations

BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer

2004 • 404 citations

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

2008 • 391 citations

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

2007 • 324 citations

Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers

2008 • 310 citations

Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy

2008 • 279 citations

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib

2007 • 277 citations

Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon Cancer

2006 • 266 citations

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

2007 • 265 citations

Molecular Determinants of Cetuximab Efficacy

2005 • 233 citations

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

2008 • 176 citations

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

2008 • 171 citations

Targeting the molecular target of rapamycin (mTOR)

2004 • 154 citations

PTEN mutations are common in sporadic microsatellite stable colorectal cancer

2004 • 151 citations

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

2008 • 90 citations

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy Number

2007 • 88 citations

Correction: Prediction of Response to Cetuximab

2008 • 54 citations

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer

2006 • 4 citations